Abstract

DEVELOPMENT AND CHARACTERIZATION OF ANTI RHEUMATOIDS DRUG BEARING SURFACE MODIFIED NANOCARRIERS SYSTEM FOR MANAGEMENT OF RHEUMATOIDS ARTHRITIS

Mandira Mallik*, Amit Verma, Sunil Kr. Jain and Vivek Jain

ABSTRACT

The aim of the current study is to gauge the development and characterization of anti rheumatoids drug bearing surface modified nanocarriers system for management of rheumatoids arthritis. Rheumatoid Arthritis (RA) is a chronic inflammatory autoimmune disease produces an inflammatory response of the symposium (synovitis) as a result destruction of articular cartilage and joints becomes swollen, warm and painful. RA is the most common form of chronic inflammatory arthritis that may affect many tissues and organs, but principally attacks sensorial joints. The process produces an inflammatory response of the symposium (synovitis) secondary to hyperplasia of synovial cells, excess synovial fluid, and the development of pannus in the synovium. From this study it may be concluded that development of folate- targeted therapeutic agents for guided intervention into arthritis may further enhance its site specific drug delivery to activated macrophages at inflamed joints in RA and may possibly used as sustained drug delivery system in rheumatoid arthritis. The developed formulation having combination of drugs can successfully employed as dual drug therapy for effectively manage the severity of disease.

Keywords: Rheumatoid Arthritis (RA), Rheumatoid Arthritis (RA) activity, Preformulation studies, folate conjugated chitosan nanoparticles.